INVENTIVA ADS/1 O.N. (F:6IVA) — Market Cap & Net Worth
Market Cap & Net Worth: INVENTIVA ADS/1 O.N. (6IVA)
INVENTIVA ADS/1 O.N. (F:6IVA) has a market capitalization of $957.19 Million (€818.74 Million) as of September 20, 2026. Listed on the F stock exchange, this Germany-based company holds position #9157 globally and #1158 in its home market, demonstrating a -2.23% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying INVENTIVA ADS/1 O.N.'s stock price €4.38 by its total outstanding shares 191925703 (191.93 Million). Also see INVENTIVA ADS/1 O.N. balance sheet assets for a full breakdown of the balance sheet.
INVENTIVA ADS/1 O.N. Market Cap History: 2020 to 2026
INVENTIVA ADS/1 O.N.'s market capitalization history from 2020 to 2026. Data shows change from $2.33 Billion to $740.46 Million (-12.26% CAGR). Also see 6IVA cash generation efficiency for how efficiently the company converts equity into cash flow.
INVENTIVA ADS/1 O.N. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how INVENTIVA ADS/1 O.N.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for INVENTIVA ADS/1 O.N. for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
161.17x
INVENTIVA ADS/1 O.N.'s market cap is 161.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.58 Billion | $4.19 Million | -$49.63 Million | 615.26x | N/A |
| 2022 | $964.84 Million | $12.18 Million | -$54.27 Million | 79.22x | N/A |
| 2023 | $825.72 Million | $17.48 Million | -$110.43 Million | 47.25x | N/A |
| 2024 | $442.03 Million | $9.20 Million | -$184.21 Million | 48.06x | N/A |
| 2025 | $722.51 Million | $4.48 Million | -$354.14 Million | 161.17x | N/A |
Competitor Companies of 6IVA by Market Capitalization
Companies near INVENTIVA ADS/1 O.N. in the global market cap rankings as of September 20, 2026. Review INVENTIVA ADS/1 O.N. (6IVA) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to INVENTIVA ADS/1 O.N. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
INVENTIVA ADS/1 O.N. Historical Marketcap From 2020 to 2026
Between 2020 and today, INVENTIVA ADS/1 O.N.'s market cap moved from $2.33 Billion to $ 740.46 Million, with a yearly change of -12.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €740.46 Million | +2.48% |
| 2025 | €722.51 Million | +63.45% |
| 2024 | €442.03 Million | -46.47% |
| 2023 | €825.72 Million | -14.42% |
| 2022 | €964.84 Million | -62.61% |
| 2021 | €2.58 Billion | +10.58% |
| 2020 | €2.33 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of INVENTIVA ADS/1 O.N. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $957.19 Million USD |
| MoneyControl | $957.19 Million USD |
| MarketWatch | $957.19 Million USD |
| marketcap.company | $957.19 Million USD |
| Reuters | $957.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About INVENTIVA ADS/1 O.N.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more